| Combination of | |
|---|---|
| Olmesartan | Angiotensin II antagonist |
| Hydrochlorothiazide | Thiazide diuretic |
| Clinical data | |
| Trade names | Benicar HCT, Benitec H, others |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Olmesartan/hydrochlorothiazide, sold under the brand name Benicar HCT among others, is a fixed-dose combination medication used to treat high blood pressure.[1][2] It is a combination of olmesartan medoxomil, an angiotensin II receptor blocker and hydrochlorothiazide, a diuretic.[2] It may be used if olmesartan is not sufficient to manage blood pressure.[3] It is taken by mouth.[3]
Common side effects include nausea, dizziness, and upper respiratory tract infections.[1] Serious side effects may include kidney problems, allergic reactions, electrolyte problems and low blood pressure.[1] Use in pregnancy is not recommended.[1] Olmesartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by increasing the loss of sodium by the kidneys.[1]
No generic version is available in the United States as of 2017.[2] In 2020, it was the 281st most commonly prescribed medication in the United States, with more than 1 million prescriptions.[4][5]
References
- 1 2 3 4 5 6 "Benicar HCT- olmesartan medoxomil-hydrochlorothiazide tablet, film coated". DailyMed. 7 September 2022. Retrieved 3 January 2023.
- 1 2 3 Bope ET, Kellerman RD (2016). Conn's Current Therapy 2017 E-Book. Elsevier Health Sciences. p. 124. ISBN 9780323443357.
- 1 2 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 177–178. ISBN 9780857113382.
- ↑ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- ↑ "Hydrochlorothiazide; Olmesartan - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.